Sanofi Partners With Maze On Oral Pompe Drug
Executive Summary
Deal Snapshot: Maze gets $150m up front in cash and equity in exchange for development and commercial rights to a GYS1 program for Pompe disease.
You may also be interested in...
US FTC Ruffles Pharma’s Feathers Again
Dust has barely settled around the uncertainty stirred up by the Federal Trade Commission’s view of the Amgen/Horizon merger and now the US regulator is taking another surprising action.
US FTC Ruffles Pharma’s Feathers Again
Dust has barely settled around the uncertainty stirred up by the Federal Trade Commission’s view of the Amgen/Horizon merger and now the US regulator is taking another surprising action.
FTC Suit Kills Sanofi/Maze Licensing Deal; Will It Doom The Pompe Candidate?
Faced with a lawsuit asserting it had acquired an asset because it was a potential threat, Sanofi bows out of agreement to develop Maze’s GYS1 inhibitor. A test for FTC’s competition theory will be whether MZE001 eventually makes it to the market through other means.